Home › Mantle Cell Lymphoma
Mantle Cell Lymphoma clinical trials recruiting in the U.S.
73 studies for Mantle Cell Lymphoma are recruiting participants at sites across the United States.
Cities with the most studies
- Baldwin Park, CA17 studies
- Houston, TX15 studies
- Durham, NC13 studies
- Seattle, WA13 studies
- Milwaukee, WI12 studies
- New York City, NY12 studies
- Boston, MA11 studies
- Columbus, OH11 studies
- Nashville, TN11 studies
- Chicago, IL10 studies
- Portland, OR9 studies
- Rochester, MN9 studies
- Denver, CO8 studies
- St. Louis, MO8 studies
- Atlanta, GA8 studies
- Salt Lake City, UT7 studies
- Cleveland, OH7 studies
- Los Angeles, CA7 studies
- Ann Arbor, MI7 studies
- Mountain View, CA7 studies
- Dallas, TX6 studies
- Miami, FL6 studies
- Jacksonville, FL6 studies
- New Haven, CT5 studies
- Baltimore, MD5 studies
- Edison, NJ5 studies
- Philadelphia, PA5 studies
- Washington, DC5 studies
- San Diego, CA5 studies
- Kansas City, MO5 studies
- Tampa, FL5 studies
- Buffalo, NY5 studies
- Queens, NY4 studies
- Charlotte, NC4 studies
- Richmond, VA4 studies
- Birmingham, AL4 studies
- Winston-Salem, NC4 studies
- Charlottesville, VA4 studies
- Omaha, NE4 studies
- Cedar Rapids, IA4 studies
By state
- Alabama4 studies
- Arizona6 studies
- California31 studies
- Colorado10 studies
- Connecticut6 studies
- Delaware3 studies
- Florida16 studies
- Georgia9 studies
- Illinois10 studies
- Indiana4 studies
- Iowa5 studies
- Kansas7 studies
- Kentucky4 studies
- Louisiana3 studies
- Maryland9 studies
- Massachusetts13 studies
- Michigan9 studies
- Minnesota14 studies
- Missouri8 studies
- Nebraska4 studies
- New Jersey8 studies
- New York16 studies
- North Carolina16 studies
- Ohio16 studies
- Oregon9 studies
- Pennsylvania9 studies
- Rhode Island4 studies
- Tennessee12 studies
- Texas19 studies
- Utah7 studies
- Virginia7 studies
- Washington15 studies
- Wisconsin13 studies
Recently updated studies
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07003295Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06263491BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT05370430A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328Auto Stem Cell Transplant for Lymphoma Patients
RecruitingPhase 2
Up to age 75 · All sexes · Updated Nov 4, 2026 · NCT03125642Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 3, 2026 · NCT05976763Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06054776A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06839053A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06742996Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Oct 29, 2026 · NCT05724121A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06564038Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Oct 26, 2026 · NCT05861050A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06697184Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04545762Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07892027Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07578077A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07424833Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06675123Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT03523975CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06026319A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07763210From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.